Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna...

As the BCMA race takes shape at ASH 2020, J&J is maintaining a leading position with the latest data for its CAR T cell candidate (cilta-cel), that is partnered with Legend. Updated data for at...

Isolating tumor antigen-specific T cellsScripps Research Institute scientists have described in Cell a method, coined FucoID, to detect and separate T cells that react to tumor-specific antigens from bystander T cells. In FucoID, which is based on...

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...

Mirati’s shares rose to an all-time high on Monday after the company dropped the latest response rate data in the closely-watched KRAS inhibitor race, but it’s still too early to tell how adagrasib (MRTX849) will...

A new fund co-founded by MD Anderson is intended to support early development of a subset of drug candidates that are not served by traditional venture capital or biopharmas, but which the cancer research...